Comparing Urogen Pharma (NASDAQ:URGN) & Gyre Therapeutics (NASDAQ:GYRE)

Gyre Therapeutics (NASDAQ:GYRE) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Earnings and Valuation

This table compares Gyre Therapeutics and Urogen Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$109.82 million	6.79	$5.03 million	($0.21)	-31.86
Urogen Pharma	$188.73 million	11.04	-$153.49 million	($1.98)	-21.54

Gyre Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Gyre Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Profitability

This table compares Gyre Therapeutics and Urogen Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Urogen Pharma	-51.73%	N/A	-43.79%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Gyre Therapeutics and Urogen Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2	0	1	0	1.67
Urogen Pharma	1	1	8	0	2.70

Gyre Therapeutics currently has a consensus target price of $16.00, indicating a potential upside of 139.16%. Urogen Pharma has a consensus target price of $52.38, indicating a potential upside of 22.83%. Given Gyre Therapeutics’ higher probable upside, equities analysts plainly believe Gyre Therapeutics is more favorable than Urogen Pharma.

Insider and Institutional Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.